SLV-308 Solvay

Current Opinion in Investigational Drugs

Volumn 4, Issue 7, 2003, Pages 878-882

  Wolf, William A ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 7 (4 METHYL 1 PIPERAZINYL) 2(3H) BENZOXAZOLONE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BENZODIOXANEMETHANAMINE DERIVATIVE; BIFEPRUNOX; BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ELTOPRAZINE; FLESINOXAN; IDAZOXAN; LEVODOPA; LISURIDE; MAZAPERTINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PLACEBO; PYRIDOPYRAZINE DERIVATIVE; QUINPIROLE; SARIZOTAN; SEROTONIN 1A AGONIST; SUNEPITRON; TANDOSPIRONE; TERGURIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANXIETY DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DYSKINESIA; HUMAN; MENTAL DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; NONHUMAN; PANIC; PARKINSON DISEASE; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPARKINSON AGENTS; BENZOXAZOLES; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; PARKINSON DISEASE; PIPERAZINES; TECHNOLOGY, PHARMACEUTICAL;

EID: 0142094602     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. 16389 The new generation of serotonergic anxiolytics: Possible clinical roles. Eison MS Psychopathol 1989 22 SUPPL 1 13-20
2. 16391 Pharmacology of the serotonergic anxiolytic tandospirone (SM-3997). Seymour PA, Mena EE, McLean S, Heym J J Prog Clin Biol Res 1990 361 453-460
3. 1A receptor ligands. Kuipers W, Van Wijngaarden I, Kruse CG, Horst-Van Amstel M, Tulp MTM, Ijzerman AP J Med Chem 1995 38 11 1942-1954
4. 2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines. Kuipers W, Kruse CG, Van Wijngaarden I, Standaar PJ, Tulp MT, Veldman N, Spek AL, Ijzerman AP J Med Chem 1997 40 3 300-312
5. 1A receptor ligands: Synthesis and structure-affinity relationships. Van Steen BJ, Van Wijngaarden I, Tulp MT, Soudijn W J Med Chem 1995 38 21 4303-4308
6. 1A receptor ligands. 2. Heterobicyclic phenylpiperazines with N4-aralkyl substituents. Van Steen BJ, Van Wijngaarden I, Tulp MTM, Soudijn W J Med Chem 1994 37 17 2761-2773
7. 285314 Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Gobert A, Rivet JM, Audinot V, Newman-Trancredi A, Cistarelli L, Millan M Neuroscience 1998 84 2 413-429
8. 330116 Annual Report 1998 - Solvay. Solvay SA Annual Report 1998 December 31
9. 342434 Drug development pipeline: Eprosartan, cilansetron, SLV-306, SLV-305, SLV-308, DU-125530, flesinoxan, DU-127090, DHT-gel, Unimed/BioChem Pharma, tedisamil, gene discovery, Solvay/Innogenetics, fluvoxamine. Solvay SA Company Communication 1999 October 04
10. 357457 Drug development pipeline: Atosiban, mazapertine, lubeluzole and ritanserin. Johnson & Johnson Company Communication 2002 February 29
11. 361829 Annual Report 1999 - Solvay SA. Solvay SA Annual Report 1999 December 31
12. 387074 Focus on value and time to market: Clinical development pipeline set to fuel sustainable growth. Merck KGaA Press Release 2000 October 26
13. 394947 Drug development pipeline: SLV-308, SLV-307. Solvay SA Company Communication 2001 January 03
14. 411282 Meiji Seika, Solvay to codevelop drug for Parkinsons disease. Pharma Jpn 2001 1747 May 28 8
15. 1A receptor in schizophrenia: A promising target for novel atypical neuroleptics? Bantick RA, Deakin JF, Grasby PM J Psychopharmacol 2001 15 1 37-46
16. 428663 SLV308: Anti-parkinsonian effects in the MPTP-treated common marmoset (Callithrix jacchus). Johnston LC, Smith L, McCreary AC, Jenner P, Ronken E Abstr Soc Neurosci 2001 27 Abs 200.3
17. 1A receptor agonism: In vitro and in vivo neurochemistry. Hesselink M, Siarey R, Glennon J, Ronken E, Von Scharrenburg G, McCreary A Abstr Soc Neurosci 2001 27 Abs 200.4
18. 428670 SLV308: A novel anti-parkinsonian agent with antidepressant and anxiolytic efficacy. McCreary A, Ronken E, Herremans A, Van Der Heyden J, Tuinstra T, Von Scharrenburg G Abstr Soc Neurosci 2001 27 Abs 200.5
19. 1A agonist improves motor complications in rodent and primate parkinsonian models. Bibbiani F, Oh JD, Chase TN Neurology 2001 57 10 1829-1834
20. 446850 Idazoxan, an α-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Rascol O, Arnulf I, Peyro-Saint Paul H, Brefel-Courbon C, Vidailhet M, Thalamas C, Bonnet AM, Descombes S, Bejjani B, Fabre N, Montrastruc JL et al. Mov Disord 2001 16 4 708-713
21. 471855 Parkinson's disease and movement disorders - Seventh International Congress (Part II), Miami, FL, USA. IDDB Meeting Report 2002 November 10-14
22. 472801 Introduction of a methyl group in α- or β-position of 1-heteroarylethyl-4-phenylpiperazines affects their dopaminergic/serotonergic properties. Roglic G, Andric D, Kostic-Rajacic S, Dukic S, Soskic V Arch Pharm (Weinheim) 2001 334 12 375-380
23. 1A activity of N-heteroarylmethyl-N-phenylpiperazines, N-heteroarylethyl-N-phenylpiperazines and N-heteroarylpropyl-N-phenylpiperazines. Roglic G, Dukic-Stefanovic S, Andric D, Kostic-Rajacic S, Soskic V Pharmazie 2001 56 10 803-807
24. 473026 DU-127090: A highly potent, atypical dopamine receptor ligand - High potency but low efficacy at dopamine D2 receptors in vitro. Van Vliet BJ, Ronken E, Tulp M, Feenstra R, Kruse CG, Long SK Eur Neuropsychopharmacol 2000 10 suppl 3 294
25. 477179 DU-127090 (Solvay/H Lundbeck). Wolf W Curr Opin Invest Drugs 2003 4 1 72-76
26. 490257 Management of early Parkinson's disease. Hauser RA, Zesiewicz TA Med Clin North Am 1999 83 2 393-414
27. 490258 Managing late complications of Parkinson's disease. Stacy M Med Clin North Am 1999 83 2 469-481
28. 1A receptor ligands. 1. Heterobicyclic phenylpiperazines with N4-alkyl substituents. Van Steen BJ, Van Wijngaarden I, Tulp MTM, Soudijn W J Med Chem 1993 36 19 2751-2760
29. 2-adrenoceptor subtype-deficient mice. Scheibner J, Trendelenburg AU, Hein L, Starke K Br J Pharmacol 2001 132 4 925-933
30. 2-Adrenoceptor modulation of 5-HT biosynthesis in the rat brain. Yoshioka M, Matsumoto M, Togashi H, Smith CB, Saito H Neurosci Lett 1992 139 1 53-56
31. 490268 Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A J Pharmacol Exp Ther 2002 303 2 791-804
32. 2-adrenoceptor. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ J Pharmacol Exp Ther 2002 303 2 805-814
33. 2, receptor subtypes. Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verriele L, Carpentier N, Millan MJ J Pharmacol Exp Ther 2002 303 2 815-822
34. 1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease. Kannari K, Kurahashi K, Tomiyama M, Maeda T, Arai A, Baba M, Suda T, Matsunaga M No To Shinkei 2002 54 2 133-137
35. 490358 EMD 128130 for the treatment of Parkinson's disease. National Institutes of Health, Bethesda, MD, USA http://www.clinicaltrials.gov
36. 492142 Drug development pipeline: SLV-308. Solvay SA Company Communication 2003 June 04